IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

BARBUT et al.

Serial No.: Not yet assigned

Filed: Submitted herewith

For: PARTIAL AORTIC OCCLUSION DEVICES AND METHODS FOR CEREBRAL PERFUSION

AUGMENTATION

Group Art Unit: Not yet assigned



INFORMATION DISCLOSURE STATEMENT

BOX PATENT APPLICATION Commissioner for Patents P.O. Box 2327 Arlington, VA 22202

Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this Information Disclosure Statement ("IDS") are brought to the attention of the Office. The items are listed on the attached form PTO-1449. In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the Patent and Trademark Office in prior Application Serial No. 09/841,929 for which a claim for priority under 35 U.S.C. §120 has been made in the instant application. Accordingly, Applicants will provide duplicate copies in respect of the present case only if the Examiner so desires.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

CERTIFICATE OF MAILING (37 C.F.R. §1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as 'Express Mail Post Office To Addressee' in an envelope addressed to the Commissioner for Patents, P.O. Box 2327, Arlington, VA 22202.

EV051624433US

Express Mail Label No.

January 18, 2002

Date of Deposit

Information Disclosure Statement Filing Provision:

filed u	three monder § 1	OS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) onths of the filing date of the application, which is not a continued prosecution application .53(d); or (2) within three months of entry of the national stage as set forth in 37 CFR § refers the mailing of a first Office action on the marity; or (4) before the mailing of a first	
1.491; or (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after filing a request for continued examination under § 1.114. Thus, no fee is required.			
		However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR §1.17(p) to the deposit account referenced below.	
		However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and a statement under 37 CFR § 1.97(e) is included below, thus no fee is required.	
on the § 1.311	merits, l	OS is being submitted under 37 CFR § 1.97(c), that is after mailing of a first Office action out before a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR	
·		The fee due under 37 CFR § 1.17(p) is submitted herewith.	
		A statement under 37 CFR § 1.97(e) is included below, thus no fee is required. In the event that this IDS is not received before a Final Action or a Notice of Allowance, then Applicant respectfully requests that the Office consider the filing of these papers to be submitted under 37 CFR § 1.97(d) and charge the fee due under 37 CFR § 1.17(p) to the deposit account below.	
This IDS is being submitted under 37 CFR § 1.97(d), that is after a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311, but before payment of the issue fee. A statement under 37 CFR § 1.97(e) is included below. The fee due under 37 CFR § 1.17(p) is submitted herewith.			
	•	STATEMENT UNDER 37 CFR § 1.97(e):	
Ш	Each it	em contained in this IDS was first cited in any communication from a foreign patent office	
in a co	unterpar	t foreign application not more than three months prior to the filing of this IDS.	
	No iter	n contained in this IDS was cited in a communication from a foreign patent office in a	
counte	rpart for	eign application, and, to the knowledge of the person signing this statement after making	
reasona	able inq	uiry, no item of information contained in this IDS was known to any individual designated	
in 37 C	CFR § 1.	56(c) more than three months prior to the filing of this IDS.	

TATMENT AND/OR AUTHORIZATION TO CHARGE FEES.			
	A check in the amount of is enclosed for the above fee(s).		
	Please charge to Deposit Account No. 12–2475 for the above fee(s).		
	The Commissioner is authorized to charge any fees required by the filing of these papers, and to		
credit any overpayment to Lyon & Lyon's Deposit Account No. 12-2475.			
	Respectfully submitted,		
	LYON & LYON LLP		
Dated:	January 18, 2002 By: John Kappos Reg. No. 37,861 Attorneys for Applicants		

LYON & LYON LLP 633 W. Fifth Street, Suite 4700 Los Angeles, CA 90071

22249

JCK/cp